Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Prospect Capital Corporation (PSEC) vs Smith & Nephew plc (SNN) Price & Performance

Prospect Capital CorporationTrade
Smith & Nephew plcTrade

Price performance (Past 24H)

Key statistics

Prospect Capital Corporation vs Smith & Nephew plc — how do they compare? Prospect Capital Corporation trades at $1.72 (market cap $974.22M), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 11.4× Prospect Capital Corporation's market cap, and Prospect Capital Corporation pays the higher dividend (23.01%). Which is the better fit depends on your goals — on Pluang, investors hold Prospect Capital Corporation for 78 Days and Smith & Nephew plc for 121 Days on average.

PSECSNN
Market Cap
$974.22M$11.10B
Volume
5,779,9961,051,703
Sector
FinancialsHealth
52-Week High
$3.05$37.17
52-Week Low
$1.82$26.42
Typical Hold Time
78 Days121 Days
Enterprise Value
$2.73B$14.13B
Dividend Yield
23.01%2.95%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Prospect Capital Corporation

PSEC trades at $1.82, down 1.09% today, with a bearish technical outlook from moving averages. The company shows mixed fundamentals with a low P/B of 0.33 but concerning revenue volatility, including a -$407M revenue in 2025. Recent quarterly EPS has consistently beaten expectations, and the company maintains regular dividend distributions. Analyst sentiment is cautious with 55% hold ratings, while technical indicators show oversold conditions with RSI below 10.

PSEC presents a high-risk opportunity with a discounted valuation and strong dividend yield, but faces significant challenges from volatile revenue performance and negative cash flow. The stock's current technical weakness and mixed analyst consensus suggest cautious approach required despite attractive yield characteristics.

Smith & Nephew plc

SNN trades at $26.96, up 0.26% on the day, but near its 52-week low amid a bearish technical signal. Recent earnings have mostly beaten expectations, with Q2 2026 EPS of $0.946 exceeding the $0.939 estimate. Revenue grew to $6.16B in 2025, and net income margin improved to 10.08%. The company continues to launch new medical products, such as the EVOS PELVIC System, to drive growth.

The outlook is mixed; strong fundamentals and product innovation support long-term value, but near-term price pressure and analyst caution pose risks. Investors should weigh robust profitability against competitive threats and recent management changes.

Returns comparison

Trailing returns across standard periods

Investor sentiment on Pluang

What Pluang investors did over the last 30 days

PSEC
95% Buy5% Sell
Avg holding period · 78 Days
SNN

No sentiment data available yet.

Top news

Latest headlines on both assets

About Prospect Capital Corporation

Prospect Capital Corp is a closed-end investment company based in the United States. Its investment objective is to generate both current income and long-term capital appreciation through debt and equity investments. The company invests primarily in senior and subordinated debt and equity of private companies for acquisitions, divestitures, growth, development, recapitalizations, and other purposes. It makes investments, including lending in private equity, sponsored transactions, directly to companies, investments in structured credit, real estate, and syndicated debt.

Read more on PSEC →

About Smith & Nephew plc

Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.

Read more on SNN →